The XmnI and BCL11A Single Nucleotide Polymorphisms May Help Predict Hydroxyurea Response in Iranian β-Thalassemia Patients

REFERENCES

• Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol. 2009;88(6):505–528.
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease and β thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, Eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Management, 2nd ed. New York: Cambridge University Press. 2009:745–754.
   Google Scholar
• Lanzkron S, Strouse JJ, Wilson R, . Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148(12):939–955.
   PubMed Web of Science ®Google Scholar
• Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95(11):3589–3593.
   Google Scholar
• Ma Q, Wyszynski DF, Farrell JJ, . Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007;7(6):386–394.
   PubMed Web of Science ®Google Scholar
• Kumkhaek C, Taylor JG, Zhu J, Hoppe C, Kato GJ, Rodgers GP. Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br J Haematol. 2008;141(2):254–259.
   PubMed Web of Science ®Google Scholar
• Uda M, Galanello R, Sanna S, . Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci USA. 2008;105(5):1620–1625.
   PubMed Web of Science ®Google Scholar
• Lettre G, Sankaran VG, Bezerra MAC, . DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA. 2008;105(33):11869–11874.
   PubMed Web of Science ®Google Scholar
• Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet. 2010;42(12):1049–1051.
   PubMed Web of Science ®Google Scholar
• Sedgewick AE, Timofeev N, Sebastiani P, . BCL11A is a major Hb F quantitative trait locus in three different populations with β-hemoglobinopathies. Blood Cells Mol Dis. 2008;41(3):255–258.
   PubMed Web of Science ®Google Scholar
• Nguyen TK, Joly P, Bardel C, Moulsma M, Bonello-Palot N, Francina A. The XmnI Gγ polymorphism influences Hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 β-thalassemia intermedia patients. Blood Cells Mol Dis. 2010;45(2):124–127.
   PubMed Web of Science ®Google Scholar
• Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol. 2009;145(4):455–467.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Menne TF, Xu J, . Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839–1842.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Xu J, Ragoczy T, . Developmental and species-divergent globin switching are driven by BCL11A. Nature. 2009;460(7259):1093–1097.
   PubMed Web of Science ®Google Scholar
• Jiang J, Best S, Menzel S, . cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108(3):1077–1083.
   PubMed Web of Science ®Google Scholar
• Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet. 2009;18(R2):R216–R223.
   PubMed Web of Science ®Google Scholar
• Bradai M, Pissard S, Abad MT, . Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830–1836.
   PubMed Web of Science ®Google Scholar
• Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica. 2004;89(10):1172–1178.
   PubMed Web of Science ®Google Scholar
• Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening. Ann Hematol. 2004;83(7):430–433.
   PubMed Web of Science ®Google Scholar
• Dixit A, Chatterjee TC, Mishra P, . Hydroxyurea in thalassemia intermedia—a promising therapy. Ann Hematol. 2005;84(7):441–446.
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Olivieri NF, . Fetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcome. Br J Haematol. 2005;131(3):378–388.
   PubMed Web of Science ®Google Scholar
• Galanello R, Sanna S, Perseu L, . Amelioration of Sardinian β0 thalassemia by genetic modifiers. Blood. 2009;114(18):3935–3937.
   PubMed Web of Science ®Google Scholar
• Badens C, Joly P, Agouti I, . Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease. Haematologica. 2011;96(11):1712–1714.
   PubMed Web of Science ®Google Scholar
• Danjou F, Anni F, Galanello R. β-Thalassemia: from genotype to phenotype. Haematologica. 2011;96(11):1573–1575.
   PubMed Web of Science ®Google Scholar
• Danjou F, Anni F, Perseu L, . Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion. Haematologica 2012 [Epub ahead of print].
   Google Scholar
• Italia KY, Jijina FJ, Merchant R, . Response to hydroxyurea in β thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009;407(1–2):10–15.
   PubMed Web of Science ®Google Scholar
• Koren A, Levin C, Dgany O, . Response to hydroxyurea therapy in β-thalassemia. Am J Hematol. 2008;83(5):366–370.
   PubMed Web of Science ®Google Scholar
• Vasavda N, Woodley C, Allman M, . Effects of co-existing α-thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids. Br J Haematol. 2011;157(2):249–252.
   Google Scholar
• Hadavi V, Taromchi AH, Malekpour M, . Elucidating the spectrum of α-thalassemia mutations in Iran. Haematologica. 2007;92(7):992–993.
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
   PubMed Web of Science ®Google Scholar
• Ye S, Dhillon S, Ke X, Collins AR, Day INM. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001;29(17):e88–e88.
   PubMed Web of Science ®Google Scholar
• Thein SL, Wood WG. The molecular basis of β thalassemia, δβ thalassemia, and hereditary persistence of fetal hemoglobin. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, Eds. Disorders of Hemoglobin, 2nd ed. New York: Cambridge University Press. 2009:323–356.
   Google Scholar
• Karimi M, Yarmohammadi H, Farjadian S, . β-Thalassemia intermedia from southern Iran: IVS-II-1 (G→A) is the prevalent thalassemia intermedia allele. Hemoglobin. 2002;26(2):147–154.
   PubMed Web of Science ®Google Scholar
• Arab A, Karimipoor M, Rajabi A, Hamid M, Arjmandi S, Zeinali S. Molecular characterization of β-thalassemia intermedia: a report from Iran. Mol Biol Rep. 2010;38(7):4321–4326.
   PubMedGoogle Scholar
• Lewis CM. Genetic association studies: design, analysis and interpretation. Brief Bioinform. 2002;3(2):146–153.
   PubMedGoogle Scholar